Fortún-Abete Jesús
Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España.
Rev Iberoam Micol. 2009 Mar 31;26(1):65-8. doi: 10.1016/S1130-1406(09)70011-7. Epub 2009 May 7.
Micafungin is an echinocandin approved for the prevention of Candida spp. infection in hematopoietic stem cell transplantation and therapy of oesophageal candidiasis, disseminated candidiasis and candidemia in adults, children and neonates.
To evaluate the role of micafungin for candidiasis therapy in solid organ transplant recipients.
A medical literature review according to micafungin role for candidiasis therapy in transplant patients is performed.
Micafungin has shown fungicide activity against Candida species, including strains resistant or poorly susceptible to fluconazole. No dose adjustment is required when micafungin is administered in combination with other drugs used in transplant patients, excluding sirolimus, nifedipine and itraconazol. With these drugs, a minimal dose reduction is recommended. The results observed in transplant patients included in clinical trials are favourable and similar to results obtained in other kind of patients.
The clinical results, its safety profile and the low grade of medical interactions permit micafungin to be considered for therapy in specific groups of transplant patients.
米卡芬净是一种棘白菌素类药物，已被批准用于预防造血干细胞移植患者的念珠菌属感染，以及治疗成人、儿童和新生儿的食管念珠菌病、播散性念珠菌病和念珠菌血症。
评估米卡芬净在实体器官移植受者念珠菌病治疗中的作用。
根据米卡芬净在移植患者念珠菌病治疗中的作用进行医学文献综述。
米卡芬净对念珠菌属具有杀菌活性，包括对氟康唑耐药或敏感性差的菌株。米卡芬净与移植患者使用的其他药物联合使用时（西罗莫司、硝苯地平和伊曲康唑除外）无需调整剂量。与这些药物合用时，建议适度减少剂量。临床试验中纳入的移植患者观察到的结果良好，与其他类型患者获得的结果相似。
临床结果、安全性以及较低的药物相互作用程度使得米卡芬净可被考虑用于特定移植患者群体的治疗。
